Particle.news
Download on the App Store
12 ARTICLES
·
last yr.

Retracted Studies Undermine Case Against FDA's Abortion Pill Approval

Two key studies cited in a legal challenge against the FDA's approval of mifepristone, the abortion pill, have been retracted, casting doubt on the case's scientific basis.

A patient prepares to take the first of two combination pills, mifepristone, for a medication abortion during a visit to a clinic in Kansas City, Kan., Oct. 12, 2022. On Monday, Oct. 30, 2023, a Kansas judge put a new state law on medication abortions on hold and blocked older restrictions that for years have spelled out what providers must tell patients and forced patients to wait 24 hours to end their pregnancies. (AP Photo/Charlie Riedel, File)
Image
Packages of Mifepristone tablets are displayed at a family planning clinic on April 13, 2023, in Rockville, Maryland.

Overview

  • Two scientific studies central to a Texas federal judge's ruling against the FDA's approval of mifepristone have been retracted by the journal publisher Sage.
  • The retraction notice cited a lack of scientific rigor and material errors in the studies, undermining their conclusions.
  • The Supreme Court is set to hear oral arguments on the case on March 26, with potential implications for access to the most common abortion method in the U.S.
  • Authors of the retracted studies, affiliated with pro-life organizations, have criticized the retractions as a 'partisan assault' on scientific research.
  • The retraction of these studies raises concerns about the use of science in validating judicial opinions and the potential impact on FDA's drug approval authority.